Chemizon Announces Research Collaboration Expansion With Takeda
LONGMONT, Colo., October 01, 2007 /PRNewswire/ -- Chemizon (010170, KOSDAQ) announced today that it has reached an agreement with Takeda Pharmaceutical Company Limited, to expand its current research collaboration focused on utilizing Chemizon's discovery platform.
As part of the agreement, Chemizon will commit a majority of its current Korean site to the Takeda partnership. In addition, Chemizon will expand its Korean operations to accommodate future growth.
"Takeda is a premier global pharmaceutical company and we are delighted that they have chosen Chemizon as a preferred partner," said Dr. Tony Piscopio, Chairman and CEO of Chemizon. "Our highly motivated scientific team's commitment to excellence remains the foundation for Chemizon's rapid growth. As we add biology capabilities to our integrated discovery platform, our partners will be able to leverage a number of additional options that will become available in the near future."
About Chemizon Inc.:
Chemizon, a division of Optomagic Co. Ltd., is a global provider of drug discovery and development capabilities to the pharmaceutical industry. Anchored by an experienced management team, Chemizon combines its vertically integrated discovery platform with a flexible, collaborative business model to develop best-in-class clinical candidates. Our expertise spans a broad range of therapeutic areas and target classes. In addition to providing an integrated discovery solution, we assist our collaborators with stand alone services including: lead optimization, library design and synthesis, custom synthesis, radiolabeling, ADME profiling, analytical method development and process chemistry.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.
Forward-looking statements
This press release may contain certain "forward-looking statements" regarding the agreement between Chemizon and Takeda Pharmaceutical Company Limited. These statements are based on Chemizon's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, collaboration potential or financial performance. None of the forward-looking statements are guaranteed, and actual results may differ materially from those projected. Chemizon may choose to update this notice in the future, based on new information, future events, or otherwise, but undertakes no obligation to do so. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Chemizon's business, including, but not limited to, the health of the global life sciences industry, the growth of the outsourcing business model and the ability of Chemizon to derive value from successful collaborations.
CONTACT: Ramesh Subramanian, VP, Business Development of Chemizon,+1-856-637-2232, sramesh@chemizon.com
Web site: http://www.chemizon.com/http://www.takeda.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
